Rafferty Asset Management
AKCA

Rafferty Asset Management’s Akcea Therapeutics Inc AKCA Stock Holding History

Rafferty Asset Management’s Portfolio AKCA Stock Details AKCA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-21,356
Closed -$362K – 883
2019
Q4 		$362K Sell
21,356
-14,501
-40% -$270K 0.01% 749
2019
Q3 		$552K Sell
35,857
-3,613
-9% -$77K 0.01% 648
2019
Q2 		$926K Buy
39,470
+15,542
+65% +$384K 0.02% 570
2019
Q1 		$678K Buy
+23,928
New +$697K 0.01% 611

Other funds holding AKCA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Rafferty Asset Management's AKCA Position: Q1 2020 in Review

Rafferty Asset Management sold out of Akcea Therapeutics Inc (AKCA) in Q1 2020, closing a stake of 21,356 shares — an estimated $362K sold.

Rafferty Asset Management first reported a position in AKCA in Q1 2019 and held it in 4 quarters. The position peaked at $926K in Q2 2019. 77 funds tracked by Wall St. Rank hold AKCA as of Q1 2020.

  • Rafferty Asset Management reported no remaining Akcea Therapeutics Inc position as of Q1 2020 after selling out during the quarter.
  • Rafferty Asset Management sold 21,356 Akcea Therapeutics Inc shares in Q1 2020, an estimated $362K.
  • Rafferty Asset Management first reported a position in Akcea Therapeutics Inc in Q1 2019 and held it in 4 quarters.
  • Rafferty Asset Management's Akcea Therapeutics Inc position peaked at $926K in Q2 2019.
  • 77 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q1 2020.

Based on Rafferty Asset Management's 13F filing for Q1 2020, filed 15 May 2020.